3M reports third-quarter results this morning before the open, with analysts penciling in $2.39 per share on revenue of $6.61 billion. Those figures imply roughly 9% earnings growth and nearly 5% revenue growth year over year. For investors focused on the income 3M throws off, however, the number on the screen matters less than what sits beneath it.
The dividend question is more interesting than it might appear at first glance. 3M currently pays $3.12 per share annually, and the last ex-dividend date was August 24, 2026. In February 2026, the board raised the quarterly dividend 7%, to $0.78 per share. That increase came after a reset: the quarterly payout was $1.50 in early 2024, then dropped to $0.70 beginning in mid-2024 around the Solventum separation, and has now begun climbing again from a lower base.
The rebuilding is genuine. In the second quarter, 3M posted adjusted EPS of $2.40 against a consensus of $2.24, a beat of more than 7%. The company also raised full-year adjusted EPS guidance after that strong showing. The industrial franchise, particularly Safety and Industrial and Transportation and Electronics, is performing. The current consensus implies EPS growth of roughly 9% against only modest revenue growth, pointing to meaningful margin expansion and operational leverage.
The complication is that two items continue to muddy the reported number: the residual Solventum stake and unresolved PFAS personal-injury litigation.
On Solventum: the change in value of 3M’s retained Solventum ownership created a $699 million year-over-year headwind in the first quarter of 2026 alone, as Solventum’s share price fell during the period. The mark-to-market swings in that stake do not affect cash, but they distort GAAP results quarter to quarter. Investors comparing GAAP to adjusted figures should expect the gap to remain wide until 3M reduces its position further.
PFAS is the harder variable. The public water supplier settlement that 3M accrued at $10.3 billion is structured as payments running from 2024 through 2036. As of October 2026, roughly 15,000 cases remain pending in the federal multidistrict litigation, the first bellwether personal-injury trial that had been set for October 20, 2025 was vacated, and court-ordered settlement talks continue with a court-appointed mediator. No global settlement covering personal-injury claims has been reached. That is the number nobody can quantify, and it is the number that matters most for dividend sustainability over a five-year horizon.
Coverage math today is actually reassuring. A $2.39 quarterly adjusted EPS run rate annualizes to roughly $9.56. The $3.12 annual dividend represents a payout ratio around 33% against that adjusted figure.
The risk is not that 3M cannot sustain $3.12 per share. At current earnings, it almost certainly can. The risk is a large, lump personal-injury settlement that forces a sudden reallocation of cash, as happened when the company reset its payout alongside the Solventum separation. In the first half of 2026, operating cash flow improved $2.6 billion year over year, partly because PFAS-related payments were lower than in the prior period. A new settlement tranche could reverse that tailwind quickly.
For long-term income investors, the practical takeaway is to treat 3M as a recovering dividend grower with a hard-to-quantify tail risk, not a mature income compounder. The 7% raise in February is a signal of management confidence. The pending litigation is a signal to size the position accordingly, rather than treat the yield as guaranteed. Today’s earnings call at 8:00 a.m. CT will be worth monitoring for any updated guidance on legal reserves and free cash flow, which together tell you far more about dividend durability than the headline EPS figure will.